MAPT and early-onset autosomal dominant Alzheimer disease: In the context of Alzheimer’s disease, laduviglusib has exhibited the ability to reduce tau phosphorylation in glutamatergic neurons, suggesting a potential role in counteracting tau accumulation, a hallmark of Alzheimer’s disease [13].